| Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study IW Flinn, R Van Der Jagt, BS Kahl, P Wood, TE Hawkins, D MacDonald, ... Blood, The Journal of the American Society of Hematology 123 (19), 2944-2952, 2014 | 665 | 2014 |
| Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for … M Crump, J Kuruvilla, S Couban, DA MacDonald, V Kukreti, CT Kouroukis, ... Journal of Clinical Oncology 32 (31), 3490-3496, 2014 | 445 | 2014 |
| Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia MA Dimopoulos, A Tedeschi, J Trotman, R García-Sanz, D Macdonald, ... New England journal of medicine 378 (25), 2399-2410, 2018 | 324 | 2018 |
| First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5 … IW Flinn, R Van Der Jagt, B Kahl, P Wood, T Hawkins, D MacDonald, ... Journal of Clinical Oncology 37 (12), 984, 2019 | 245 | 2019 |
| Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial MA Dimopoulos, J Trotman, A Tedeschi, JV Matous, D Macdonald, C Tam, ... The Lancet Oncology 18 (2), 241-250, 2017 | 234 | 2017 |
| Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas RD Morin, S Assouline, M Alcaide, A Mohajeri, RL Johnston, L Chong, ... Clinical cancer research 22 (9), 2290-2300, 2016 | 228 | 2016 |
| Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma SE Assouline, TH Nielsen, S Yu, M Alcaide, L Chong, D MacDonald, ... Blood, The Journal of the American Society of Hematology 128 (2), 185-194, 2016 | 150 | 2016 |
| Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study A Davies, F Merli, B Mihaljevic, N Siritanaratkul, P Solal-Céligny, M Barrett, ... The lancet oncology 15 (3), 343-352, 2014 | 147 | 2014 |
| Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group D Villa, M Crump, T Panzarella, KJ Savage, CL Toze, DA Stewart, ... J Clin Oncol 31 (9), 1164-1171, 2013 | 126 | 2013 |
| Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial A Davies, F Merli, B Mihaljević, S Mercadal, N Siritanaratkul, ... The Lancet Haematology 4 (6), e272-e282, 2017 | 101 | 2017 |
| Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study C Buske, A Tedeschi, J Trotman, R García-Sanz, D MacDonald, ... Journal of Clinical Oncology 40 (1), 52, 2022 | 82 | 2022 |
| Spectrum of CT findings in thoracic extranodal non-Hodgkin lymphoma MP Bligh, JN Borgaonkar, SC Burrell, DA MacDonald, D Manos Radiographics 37 (2), 439-461, 2017 | 66 | 2017 |
| iNNOVATE Study Group and the European Consortium for Waldenstr öm’s Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenstr öm’s macroglobulinaemia … MA Dimopoulos, J Trotman, A Tedeschi, JV Matous, D Macdonald, C Tam, ... Lancet Oncol 18 (2), 241-250, 2017 | 63 | 2017 |
| Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma R Herbrecht, P Cernohous, A Engert, S Le Gouill, D Macdonald, ... Annals of oncology 24 (10), 2618-2623, 2013 | 60 | 2013 |
| An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide … IW Flinn, RH Van der Jagt, BS Kahl, P Wood, TE Hawkins, D MacDonald, ... Blood 120 (21), 902, 2012 | 54 | 2012 |
| Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12 J Kuruvilla, DA MacDonald, CT Kouroukis, M Cheung, HJ Olney, ... Blood, The Journal of the American Society of Hematology 126 (6), 733-738, 2015 | 52 | 2015 |
| A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National … DA Macdonald, SE Assouline, J Brandwein, S Kamel-Reid, ... Leukemia & lymphoma 54 (4), 760-766, 2013 | 52 | 2013 |
| Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma P Skrabek, S Assouline, A Christofides, D MacDonald, A Prica, R Sangha, ... Current Oncology 26 (4), 253-265, 2019 | 50 | 2019 |
| First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. I Flinn, R van der Jagt, JE Chang, P Wood, TE Hawkins, D MacDonald, ... Journal of Clinical Oncology 35 (15_suppl), 7500-7500, 2017 | 46 | 2017 |
| iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia MA Dimopoulos, A Tedeschi, J Trotman, R García-Sanz, D Macdonald, ... N Engl J Med 378 (25), 2399-2410, 2018 | 45 | 2018 |
